Cost-effectiveness of GRAZAX ® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe
Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disea...
Uloženo v:
| Vydáno v: | Respiratory medicine Ročník 101; číslo 9; s. 1885 - 1894 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Oxford
Elsevier Ltd
01.09.2007
Elsevier Elsevier Limited |
| Témata: | |
| ISSN: | 0954-6111, 1532-3064 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax
® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax
® in four Southern European countries.
A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax
®. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs).
Grazax
® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax
® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season.
The analysis illustrates that allergen SIT with Grazax
® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. |
|---|---|
| AbstractList | Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax® in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax® . Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax® was cost-effective for all countries for an annual price in the range of &z.euro;1500-&z.euro;1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax ® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax ® in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax ®. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax ® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax ® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax ® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Summary Background Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax® from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax® in four Southern European countries. Methods A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax® . Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Results Grazax® was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax® was cost-effective for all countries for an annual price in the range of €1500–€1900. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. Conclusion The analysis illustrates that allergen SIT with Grazax® for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax in four Southern European countries.BACKGROUNDAllergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax in four Southern European countries.A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs).METHODSA prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs).Grazax was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax was cost-effective for all countries for an annual price in the range of 1500 euros - 1900 euros. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season.RESULTSGrazax was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax was cost-effective for all countries for an annual price in the range of 1500 euros - 1900 euros. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season.The analysis illustrates that allergen SIT with Grazax for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe.CONCLUSIONThe analysis illustrates that allergen SIT with Grazax for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced allergic rhinitis. Standard care only provides symptoms relief, while allergen specific immunotherapy (SIT) treats the underlying cause of the disease. Grazax from ALK-Abelló is a new, tablet-based, effective route of SIT for home treatment. The objective was to assess the cost-effectiveness of Grazax in four Southern European countries. A prospective pharmacoeconomic analyses was carried out alongside a multinational, clinical trial measuring the efficacy of Grazax. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a nine-year time horizon. The primary outcome measure was quality adjusted life years (QALYs). Grazax was superior to standard care for all efficacy endpoints, including QALYs gained, and resulted in significantly less use of rescue medication and fewer hours missed from work. Grazax was cost-effective for all countries for an annual price in the range of 1500 euros - 1900 euros. The result was improved by inclusion of future costs of asthma and exclusion of Spanish trial centers which experienced an exceptionally low pollen season. The analysis illustrates that allergen SIT with Grazax for grass pollen induced rhinoconjunctivitis is a cost-effective intervention in Southern Europe. |
| Author | Poulsen, P.B. Canonica, G.W. Vestenbæk, U. |
| Author_xml | – sequence: 1 givenname: G.W. surname: Canonica fullname: Canonica, G.W. organization: Allergy & Respiratory Diseases Clinic, DIMI, University of Genova, Pad.Maragliano, L.go R.Benzi 10, 16132 Genoa, Italy – sequence: 2 givenname: P.B. surname: Poulsen fullname: Poulsen, P.B. email: pbpo@muusmann.com organization: MUUSMANN Research & Consulting, Haderslevvej 36, DK-6000 Kolding, Denmark – sequence: 3 givenname: U. surname: Vestenbæk fullname: Vestenbæk, U. organization: ALK-Abelló, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18987438$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17611095$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkt9qFDEYxYNU7Lb6Al7IgOjdjF_-zD8RYVlqFQqC7YV4E7KZLzbrbDJNZgp9KR_CJzPDrhYWrFeBfL9zkpyTE3LkvENCnlMoKNDqzaYIW-wKBlAXUBYA_BFZ0JKznEMljsgC2lLkFaX0mJzEuAGAVgh4Qo5pnXbTdEG2Kx_HHI1BPdpbdBhj5k12_mX5bfk1-_UzMz5kQ8A0Gq138-x7UAkafN-jy6zrJo1dFq6t89q7zeRmIzvamGbZpZ_GawwuO5uCH_ApeWxUH_HZfj0lVx_OrlYf84vP559Wy4tcl40Yc9ZRLTowJWuxgTWKWkPb8EZpxltVK9BrRNOZlirOqNHQdUKVbdVohryi_JS83tkOwd9MGEe5tVFj3yuHfoqyaigXTFQJfHkAbvwUXLqapMBLEDUTPFEv9tS0ToHLIditCnfyT4oJeLUHVNSqN0E5beM917RNLXiTuGbH6eBjDGiktqOacx2Dsn06U87Fyo2ci5VzsRJKmYpNUnYg_ev-kOjdToQp61uLQUZt0aW-bEh9y87bh-XvD-S6t86mF_7AO4z3UcnIJMjL-bvNvw1qANqCSAZv_23wv9N_A-jz5VI |
| CitedBy_id | crossref_primary_10_3310_hta20670 crossref_primary_10_1097_MOO_0000000000000150 crossref_primary_10_1111_all_14246 crossref_primary_10_1111_j_1398_9995_2012_02861_x crossref_primary_10_1186_1939_4551_7_6 crossref_primary_10_1016_j_jaci_2010_09_033 crossref_primary_10_4137_EHI_S16486 crossref_primary_10_1111_all_13254 crossref_primary_10_1007_s40273_013_0084_z crossref_primary_10_1016_j_jval_2020_06_001 crossref_primary_10_2165_00151234_200705370_00017 crossref_primary_10_1016_j_jaci_2010_09_037 crossref_primary_10_1016_j_jaci_2015_12_1300 crossref_primary_10_33590_emj_10314632 crossref_primary_10_1111_j_1398_9995_2009_02232_x crossref_primary_10_1007_s11882_019_0893_z crossref_primary_10_1016_j_mcna_2019_09_001 crossref_primary_10_1016_j_iac_2019_09_003 crossref_primary_10_1097_ACI_0000000000000785 crossref_primary_10_1016_j_jaci_2011_10_045 crossref_primary_10_1097_01_WOX_0000365038_00251_8a crossref_primary_10_1016_j_drudis_2015_07_010 crossref_primary_10_1097_ACI_0b013e32831411e9 crossref_primary_10_1097_01_WOX_0000365049_40480_36 crossref_primary_10_1111_j_1365_2222_2011_03794_x crossref_primary_10_1136_adc_2010_183095 crossref_primary_10_1080_09286586_2020_1792938 crossref_primary_10_1186_1710_1492_6_29 crossref_primary_10_1111_all_13201 crossref_primary_10_1016_S1081_1206_10_60498_X crossref_primary_10_1080_1744666X_2021_1886079 crossref_primary_10_1111_all_15985 crossref_primary_10_1111_j_1398_9995_2011_02590_x crossref_primary_10_2217_imt_2022_0143 crossref_primary_10_1016_S1081_1206_10_60190_1 crossref_primary_10_1371_journal_pone_0131949 crossref_primary_10_1097_WOX_0b013e3181c6c379 crossref_primary_10_1097_WOX_0b013e31816d92d6 crossref_primary_10_1097_01_WOX_0000365050_48103_34 crossref_primary_10_1186_s12948_016_0057_9 crossref_primary_10_1097_ACI_0b013e3283196a9b crossref_primary_10_1186_s13601_015_0045_z crossref_primary_10_1186_s12948_015_0016_x |
| Cites_doi | 10.1067/mai.2002.121317 10.1136/bmj.302.6771.265 10.1034/j.1398-9995.2002.23664.x 10.1056/NEJM199908123410702 10.1016/S1081-1206(10)63282-6 10.1038/sj.jhh.1001178 10.2165/00019053-199507010-00001 10.2165/00019053-200017010-00002 10.1183/09031936.02.02542001 10.1111/j.1398-9995.1988.tb01631.x 10.2174/187152806775269286 10.1177/009286150103500122 10.1111/j.1398-9995.1998.tb03886.x 10.1067/mai.2001.118891 10.1016/0168-8510(96)00822-6 10.1378/chest.111.2_Supplement.11S 10.2165/00019053-199508030-00007 10.1183/09031936.04.00116203 10.1016/j.jaci.2005.12.1358 10.1111/j.1398-9995.2005.00949.x 10.1111/j.1398-9995.2003.00468.x 10.1053/rmed.2001.1031 10.1183/09031936.04.00013904 10.1046/j.1365-2222.2003.01587.x 10.1111/j.1398-9995.2006.01068.x 10.1016/j.jaci.2006.01.023 10.1016/S1081-1206(10)63136-5 10.1016/S0091-6749(98)70218-0 10.1016/j.jaci.2004.07.012 10.1542/peds.2004-2709 10.1183/09031936.98.12061322 10.1067/mai.2003.129 10.1111/j.1742-1241.2005.00347.x 10.1111/j.1398-9995.2006.01053.x 10.1183/09031936.04.00004904 10.1007/s11136-006-9110-3 10.1016/j.jaci.2006.05.003 10.1111/j.1398-9995.1995.tb01170.x 10.1016/S1081-1206(10)61090-3 |
| ContentType | Journal Article |
| Copyright | 2007 2007 INIST-CNRS Copyright Elsevier Limited Sep 2007 |
| Copyright_xml | – notice: 2007 – notice: 2007 INIST-CNRS – notice: Copyright Elsevier Limited Sep 2007 |
| DBID | 6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 ASE FPQ H94 K6X K9. M7N NAPCQ 7X8 |
| DOI | 10.1016/j.rmed.2007.05.003 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts British Nursing Index British Nursing Index (BNI) (1985 to Present) AIDS and Cancer Research Abstracts British Nursing Index ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-3064 |
| EndPage | 1894 |
| ExternalDocumentID | 2745006421 17611095 18987438 10_1016_j_rmed_2007_05_003 S0954611107001904 1_s2_0_S0954611107001904 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Europe |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI CAG COF CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMK HMO HVGLF HZ~ IHE IXB J1W K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OI- OK1 OU. OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ RSU SAE SDF SDG SEL SES SEW SPCBC SSH SSZ SV3 T5K UHS UV1 WH7 WOW WUQ X7M Z5R ZGI ZXP ~G- ~HD 0SF 3V. 6I. 7RV 7X7 AACTN AAFTH ABVKL AFCTW AFKRA AFKWA AJOXV AMFUW BENPR M0T M2O NCXOZ RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU LCYCR ZA5 9DU AAYXX CITATION AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7U9 ASE FPQ H94 K6X K9. M7N NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c584t-2d1c4d0f529e80be47c09838ac239a7a0cbeefdf91a321fc0dd4a5968c2e3613 |
| ISICitedReferencesCount | 49 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000249092300005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0954-6111 |
| IngestDate | Thu Oct 02 18:06:02 EDT 2025 Sat Nov 29 14:25:26 EST 2025 Mon Jul 21 06:05:26 EDT 2025 Mon Jul 21 09:16:10 EDT 2025 Sat Nov 29 07:08:57 EST 2025 Tue Nov 18 22:14:05 EST 2025 Fri Feb 23 02:31:37 EST 2024 Sun Feb 23 10:19:32 EST 2025 Tue Oct 14 19:33:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | QALY Grass pollen allergy Rhinoconjunctivitis Allergen specific immunotherapy Cost-effectiveness Grass allergen tablet Allergy Nose disease Rhinitis Conjunctiva disease Conjunctivitis Prevention Immunotherapy ENT disease Tablet Pollen Public health Cost efficiency analysis Pneumology Immunopathology South Eye disease Treatment Health economy Dosage form Allergen |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c584t-2d1c4d0f529e80be47c09838ac239a7a0cbeefdf91a321fc0dd4a5968c2e3613 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.rmed.2007.05.003 |
| PMID | 17611095 |
| PQID | 1035047243 |
| PQPubID | 1216389 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_68134246 proquest_journals_1035047243 pubmed_primary_17611095 pascalfrancis_primary_18987438 crossref_citationtrail_10_1016_j_rmed_2007_05_003 crossref_primary_10_1016_j_rmed_2007_05_003 elsevier_sciencedirect_doi_10_1016_j_rmed_2007_05_003 elsevier_clinicalkeyesjournals_1_s2_0_S0954611107001904 elsevier_clinicalkey_doi_10_1016_j_rmed_2007_05_003 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-09-01 |
| PublicationDateYYYYMMDD | 2007-09-01 |
| PublicationDate_xml | – month: 09 year: 2007 text: 2007-09-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | Respiratory medicine |
| PublicationTitleAlternate | Respir Med |
| PublicationYear | 2007 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Dahl, Stender, Rak (bib24) 2006; 61 Antonicelli, Bucca, Neri (bib41) 2004; 23 Durham, Yang, Pedersen, Johansen, Rak (bib23) 2006; 117 Bousquet, Lockey, Malling (bib11) 1998; 81 Sculpher (bib48) 2006; 61 Donahue, Greineder, Connor-Lacke, Canning, Platt (bib51) 1999; 82 Durham, Walker, Varga (bib14) 1999; 34 Drummond, Sculpher, Torrance, O′Brien, Stoddart (bib32) 2005 Instituto Nacional de Meteorologia. El año más seco, Noticias; 2006. Guide to the methods of technology appraisal. National Institute of Clinical Excellence, April 2004. Stock, Redaelli, Luengen, Wendland, Civello, Lauterbach (bib42) 2005; 25 Varney, Gaga, Frew, Aber, Kay, Durham (bib12) 1991; 302 Serra-Batles, Plaza, Morejon, Comella (bib37) 1998; 12 Canonica, Passalacqua (bib20) 2003; 111 Lindgren, Sears, Campbell, Villasante, Huang, Lindh (bib35) 2005; 59 Conference report, Scottish medicines consortium completes four year's work, vol. 10(1). IMS Health, PHARMA Pricing & Reimbursement; 2006. Berto, Passalacqua, Crimi (bib22) 2006; 97 Garattini, Grilli, Scopelliti, Mantovani (bib28) 1995; 7 Van Ganse, Laforest, Pietri (bib38) 2002; 20 . Rak, Yang, Pedersen, Durham (bib25) 2007; 16 Grossman (bib8) 1997; 111 Collége des Èconomistes de la Santé (CES). French guidelines for the economic evaluation of health care technologies, September 2004. Marshall JB. European allergy white paper. Allergic diseases as a public health problem in Europe. The UCG Institute of Allergy, May 1997. Di-Rienzo, Marcucci, Puccinelli (bib15) 2003; 33 Walker, Varney, Gaga, Jacobson, Durham (bib13) 1995; 50 Möller, Dreborg, Ferdousi (bib16) 2002; 109 Niggemann, Jacobsen, Dreborg (bib17) 2006; 61 Linneberg, Nielsen, Frølund, Madsen, Dirksen, Jørgensen (bib6) 2002; 57 Dahl, Kapp, Colombo (bib26) 2006; 118 EFA (European Federation of Allergy and Airway Diseases Patients Association). Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report; 2005. Galassi, De Sario, Biggeri (bib4) 2006; 117 Heyse, Cook, Carides (bib43) 2001 Capri, Ceci, Terranova, Merlo, Mantovani (bib27) 2001; 35 Gonzáles Minero, Candau, Thomás, Morales (bib47) 1998; 53 Pinotti M, Vercilli F. Nuovo nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Direzione Medica di Presidio; 2004. Royal College of Physicians. Allergy: the unmet need, a blueprint for better patient care, June 2003. Mosbech, Østerballe (bib33) 1988; 43 Bauchau, Durham (bib3) 2004; 24 Coons, Rao, Keininger, Hays (bib44) 2000; 17 Valovirta, Jacobsen, Niggemann (bib18) 2006; 117 Brooks (bib45) 1996; 37 Rovira, Antoñanzas (bib29) 1995; 8 Bousquet, van Cauwenberge, Khaltaev (bib1) 2001; 108 Linneberg, Nielsen, Madsen, Frølund, Dirksen, Jørgensen (bib39) 2001; 95 ALK-Abelló. GT-08 Integrated clinical trial report, pollen season 2005. Final 16, October 2005. Bousquet (bib10) 2004; 59 Degli Esposti, Berto, Ruffo, Buda, Degli Esposti, Sturani (bib34) 2001; 15 Passalacqua, Guerra, Pasquali, Canonica (bib21) 2006; 5 Bousquet J, van Cauwenberge PB, Khaltaev N, et al. The management of allergic rhinitis symptoms in the pharmacy, Paris, October 23, 2002. Novembre, Galli, Landi (bib40) 2004; 114 Corren (bib7) 1998; 101 Rak (10.1016/j.rmed.2007.05.003_bib25) 2007; 16 Rovira (10.1016/j.rmed.2007.05.003_bib29) 1995; 8 Drummond (10.1016/j.rmed.2007.05.003_bib32) 2005 Walker (10.1016/j.rmed.2007.05.003_bib13) 1995; 50 Berto (10.1016/j.rmed.2007.05.003_bib22) 2006; 97 Bousquet (10.1016/j.rmed.2007.05.003_bib11) 1998; 81 10.1016/j.rmed.2007.05.003_bib46 Garattini (10.1016/j.rmed.2007.05.003_bib28) 1995; 7 10.1016/j.rmed.2007.05.003_bib2 Coons (10.1016/j.rmed.2007.05.003_bib44) 2000; 17 Brooks (10.1016/j.rmed.2007.05.003_bib45) 1996; 37 10.1016/j.rmed.2007.05.003_bib5 10.1016/j.rmed.2007.05.003_bib9 Bousquet (10.1016/j.rmed.2007.05.003_bib10) 2004; 59 Lindgren (10.1016/j.rmed.2007.05.003_bib35) 2005; 59 Serra-Batles (10.1016/j.rmed.2007.05.003_bib37) 1998; 12 Capri (10.1016/j.rmed.2007.05.003_bib27) 2001; 35 Gonzáles Minero (10.1016/j.rmed.2007.05.003_bib47) 1998; 53 Bousquet (10.1016/j.rmed.2007.05.003_bib1) 2001; 108 Galassi (10.1016/j.rmed.2007.05.003_bib4) 2006; 117 10.1016/j.rmed.2007.05.003_bib49 Grossman (10.1016/j.rmed.2007.05.003_bib8) 1997; 111 Dahl (10.1016/j.rmed.2007.05.003_bib26) 2006; 118 Corren (10.1016/j.rmed.2007.05.003_bib7) 1998; 101 Heyse (10.1016/j.rmed.2007.05.003_bib43) 2001 Antonicelli (10.1016/j.rmed.2007.05.003_bib41) 2004; 23 Novembre (10.1016/j.rmed.2007.05.003_bib40) 2004; 114 10.1016/j.rmed.2007.05.003_bib50 Möller (10.1016/j.rmed.2007.05.003_bib16) 2002; 109 Linneberg (10.1016/j.rmed.2007.05.003_bib39) 2001; 95 Linneberg (10.1016/j.rmed.2007.05.003_bib6) 2002; 57 Di-Rienzo (10.1016/j.rmed.2007.05.003_bib15) 2003; 33 10.1016/j.rmed.2007.05.003_bib19 Stock (10.1016/j.rmed.2007.05.003_bib42) 2005; 25 Niggemann (10.1016/j.rmed.2007.05.003_bib17) 2006; 61 Canonica (10.1016/j.rmed.2007.05.003_bib20) 2003; 111 Sculpher (10.1016/j.rmed.2007.05.003_bib48) 2006; 61 Valovirta (10.1016/j.rmed.2007.05.003_bib18) 2006; 117 Varney (10.1016/j.rmed.2007.05.003_bib12) 1991; 302 Donahue (10.1016/j.rmed.2007.05.003_bib51) 1999; 82 Durham (10.1016/j.rmed.2007.05.003_bib14) 1999; 34 Durham (10.1016/j.rmed.2007.05.003_bib23) 2006; 117 Bauchau (10.1016/j.rmed.2007.05.003_bib3) 2004; 24 Passalacqua (10.1016/j.rmed.2007.05.003_bib21) 2006; 5 Van Ganse (10.1016/j.rmed.2007.05.003_bib38) 2002; 20 Degli Esposti (10.1016/j.rmed.2007.05.003_bib34) 2001; 15 10.1016/j.rmed.2007.05.003_bib36 10.1016/j.rmed.2007.05.003_bib31 10.1016/j.rmed.2007.05.003_bib30 Dahl (10.1016/j.rmed.2007.05.003_bib24) 2006; 61 Mosbech (10.1016/j.rmed.2007.05.003_bib33) 1988; 43 |
| References_xml | – volume: 15 start-page: 329 year: 2001 end-page: 334 ident: bib34 article-title: The PANDORA project: results of the cost of illness analysis publication-title: J Hum Hypertension – volume: 33 start-page: 206 year: 2003 end-page: 210 ident: bib15 article-title: Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study publication-title: Clin Exp Allergy – volume: 108 start-page: S147 year: 2001 end-page: S334 ident: bib1 article-title: Allergic rhinitis and its impact on asthma publication-title: J Allergy Clin Immunol – volume: 37 start-page: 53 year: 1996 end-page: 72 ident: bib45 article-title: EuroQol: the current state of play publication-title: Health Policy – volume: 35 start-page: 189 year: 2001 end-page: 201 ident: bib27 article-title: Guidelines for economic evaluation in Italy: recommendations from the Italian group of pharmacoeconomic studies publication-title: Drug Inf J – volume: 61 start-page: 527 year: 2006 end-page: 530 ident: bib48 article-title: The use of quality-adjusted life-years in cost-effectiveness studies publication-title: Allergy – reference: ALK-Abelló. GT-08 Integrated clinical trial report, pollen season 2005. Final 16, October 2005. – volume: 111 start-page: 437 year: 2003 end-page: 448 ident: bib20 article-title: Noninjection routes for immunotherapy publication-title: J Allergy Clin Immunol – reference: Pinotti M, Vercilli F. Nuovo nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Direzione Medica di Presidio; 2004. – reference: 〉. – volume: 53 start-page: 266 year: 1998 end-page: 274 ident: bib47 article-title: Airborne grass (Poaceae) pollen in southern Spain. Results of a 10-year study (1987–1996) publication-title: Allergy – volume: 12 start-page: 1322 year: 1998 end-page: 1326 ident: bib37 article-title: Brugues J: cost of asthma according to the degree of severity publication-title: Eur Respir J – volume: 61 start-page: 185 year: 2006 end-page: 190 ident: bib24 article-title: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis publication-title: Allergy – reference: Conference report, Scottish medicines consortium completes four year's work, vol. 10(1). IMS Health, PHARMA Pricing & Reimbursement; 2006. – volume: 109 start-page: 251 year: 2002 end-page: 256 ident: bib16 article-title: Pollen allergen specific immunotherapy reduces the development of asthma in children with seasonal rhinitis. The PAT-study publication-title: J Allergy Clin Immunol – volume: 117 start-page: 721 year: 2006 ident: bib18 article-title: A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study publication-title: J Allergy Clin Immunol – volume: 114 start-page: 851 year: 2004 end-page: 857 ident: bib40 article-title: Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol – volume: 59 start-page: 62 year: 2005 end-page: 68 ident: bib35 article-title: Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and Spain publication-title: Int J Clin Practice – volume: 34 start-page: 468 year: 1999 end-page: 475 ident: bib14 article-title: Long-term clinical efficacy of grass-pollen allergen specific immunotherapy publication-title: N Engl J Med – volume: 117 start-page: 34 year: 2006 end-page: 42 ident: bib4 article-title: Changes in the prevalence of asthma and allergies among children and adolescents in Italy: 1999–2002 publication-title: Pediatrics – volume: 16 start-page: 191 year: 2007 end-page: 201 ident: bib25 article-title: Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study publication-title: Qual Life Res – volume: 118 start-page: 434 year: 2006 end-page: 440 ident: bib26 article-title: Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol – volume: 7 start-page: 1 year: 1995 end-page: 6 ident: bib28 article-title: A proposal for Italian Guidelines in pharmacoeconomics publication-title: Pharmacoeconomics – volume: 5 start-page: 43 year: 2006 end-page: 51 ident: bib21 article-title: Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy publication-title: Inflamm Allergy Drug Targets – volume: 117 start-page: 802 year: 2006 end-page: 809 ident: bib23 article-title: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol – reference: Collége des Èconomistes de la Santé (CES). French guidelines for the economic evaluation of health care technologies, September 2004. – volume: 57 start-page: 1048 year: 2002 end-page: 1052 ident: bib6 article-title: The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study publication-title: Allergy – reference: EFA (European Federation of Allergy and Airway Diseases Patients Association). Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report; 2005. 〈 – reference: Royal College of Physicians. Allergy: the unmet need, a blueprint for better patient care, June 2003. – volume: 20 start-page: 260 year: 2002 end-page: 267 ident: bib38 article-title: Persistent asthma: disease control, resource utilisation and direct costs publication-title: Eur Respir J – volume: 59 start-page: 373 year: 2004 end-page: 387 ident: bib10 article-title: ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma publication-title: Allergy – year: 2005 ident: bib32 article-title: Methods for the economic evaluation of health care programmes – volume: 111 start-page: 6 year: 1997 end-page: 11 ident: bib8 article-title: One airway, one disease publication-title: Chest – volume: 81 start-page: 401 year: 1998 end-page: 405 ident: bib11 article-title: Allergen specific immunotherapy: therapeutic vaccines for allergic diseases allergy, World Health Organization and American Academy of Allergy, asthma and immunology publication-title: Ann Allergy Asthma Immunol – reference: Guide to the methods of technology appraisal. National Institute of Clinical Excellence, April 2004. – volume: 95 start-page: 258 year: 2001 end-page: 264 ident: bib39 article-title: Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study publication-title: Respir Med – reference: Bousquet J, van Cauwenberge PB, Khaltaev N, et al. The management of allergic rhinitis symptoms in the pharmacy, Paris, October 23, 2002. – year: 2001 ident: bib43 article-title: Statistical considerations in analysing health care resource utilization and cost data publication-title: Economic evaluation in health care. Merging theory with practice – volume: 43 start-page: 523 year: 1988 end-page: 529 ident: bib33 article-title: Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis publication-title: Allergy – volume: 61 start-page: 855 year: 2006 end-page: 859 ident: bib17 article-title: Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children publication-title: Allergy – volume: 97 start-page: 615 year: 2006 end-page: 621 ident: bib22 article-title: Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the SPAI study publication-title: Ann Allergy Asthma Immunol – volume: 25 start-page: 47 year: 2005 end-page: 53 ident: bib42 article-title: Asthma: prevalence and cost of illness publication-title: Eur Respir J – volume: 82 start-page: 339 year: 1999 end-page: 347 ident: bib51 article-title: Utilization and cost of immunotherapy for allergic asthma and rhinitis publication-title: Ann Allergy Asthma Immunol – volume: 302 start-page: 265 year: 1991 end-page: 269 ident: bib12 article-title: Usefulness of allergen specific immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs publication-title: BMJ – volume: 101 start-page: 352 year: 1998 end-page: 356 ident: bib7 article-title: The impact of allergic rhinitis on bronchial asthma publication-title: J Allergy Clin Immunol – volume: 50 start-page: 405 year: 1995 end-page: 413 ident: bib13 article-title: Grass pollen allergen specific immunotherapy. Efficacy and safety during a 4-year follow-up study publication-title: Allergy – volume: 23 start-page: 723 year: 2004 end-page: 729 ident: bib41 article-title: Asthma severity and medical resource utilisation publication-title: Eur Respir J – reference: Instituto Nacional de Meteorologia. El año más seco, Noticias; 2006. 〈 – volume: 24 start-page: 758 year: 2004 end-page: 764 ident: bib3 article-title: Prevalence and rate of diagnosis of allergic rhinitis in Europe publication-title: Eur Respir J – volume: 8 start-page: 245 year: 1995 end-page: 252 ident: bib29 article-title: Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation publication-title: Pharmacoeconomics – volume: 17 start-page: 13 year: 2000 end-page: 35 ident: bib44 article-title: A comparative review of generic quality-of-life instruments publication-title: Pharmacoeconomics – reference: Marshall JB. European allergy white paper. Allergic diseases as a public health problem in Europe. The UCG Institute of Allergy, May 1997. – year: 2005 ident: 10.1016/j.rmed.2007.05.003_bib32 – volume: 109 start-page: 251 issue: 2 year: 2002 ident: 10.1016/j.rmed.2007.05.003_bib16 article-title: Pollen allergen specific immunotherapy reduces the development of asthma in children with seasonal rhinitis. The PAT-study publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2002.121317 – ident: 10.1016/j.rmed.2007.05.003_bib36 – ident: 10.1016/j.rmed.2007.05.003_bib2 – volume: 302 start-page: 265 issue: 6771 year: 1991 ident: 10.1016/j.rmed.2007.05.003_bib12 article-title: Usefulness of allergen specific immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs publication-title: BMJ doi: 10.1136/bmj.302.6771.265 – ident: 10.1016/j.rmed.2007.05.003_bib46 – volume: 57 start-page: 1048 year: 2002 ident: 10.1016/j.rmed.2007.05.003_bib6 article-title: The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study publication-title: Allergy doi: 10.1034/j.1398-9995.2002.23664.x – volume: 34 start-page: 468 issue: 7 year: 1999 ident: 10.1016/j.rmed.2007.05.003_bib14 article-title: Long-term clinical efficacy of grass-pollen allergen specific immunotherapy publication-title: N Engl J Med doi: 10.1056/NEJM199908123410702 – volume: 82 start-page: 339 year: 1999 ident: 10.1016/j.rmed.2007.05.003_bib51 article-title: Utilization and cost of immunotherapy for allergic asthma and rhinitis publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)63282-6 – volume: 15 start-page: 329 issue: 5 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib34 article-title: The PANDORA project: results of the cost of illness analysis publication-title: J Hum Hypertension doi: 10.1038/sj.jhh.1001178 – volume: 7 start-page: 1 year: 1995 ident: 10.1016/j.rmed.2007.05.003_bib28 article-title: A proposal for Italian Guidelines in pharmacoeconomics publication-title: Pharmacoeconomics doi: 10.2165/00019053-199507010-00001 – ident: 10.1016/j.rmed.2007.05.003_bib5 – volume: 17 start-page: 13 issue: 1 year: 2000 ident: 10.1016/j.rmed.2007.05.003_bib44 article-title: A comparative review of generic quality-of-life instruments publication-title: Pharmacoeconomics doi: 10.2165/00019053-200017010-00002 – volume: 20 start-page: 260 issue: 2 year: 2002 ident: 10.1016/j.rmed.2007.05.003_bib38 article-title: Persistent asthma: disease control, resource utilisation and direct costs publication-title: Eur Respir J doi: 10.1183/09031936.02.02542001 – volume: 43 start-page: 523 issue: 7 year: 1988 ident: 10.1016/j.rmed.2007.05.003_bib33 article-title: Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis publication-title: Allergy doi: 10.1111/j.1398-9995.1988.tb01631.x – ident: 10.1016/j.rmed.2007.05.003_bib9 – ident: 10.1016/j.rmed.2007.05.003_bib50 – volume: 5 start-page: 43 issue: 1 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib21 article-title: Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy publication-title: Inflamm Allergy Drug Targets doi: 10.2174/187152806775269286 – volume: 35 start-page: 189 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib27 article-title: Guidelines for economic evaluation in Italy: recommendations from the Italian group of pharmacoeconomic studies publication-title: Drug Inf J doi: 10.1177/009286150103500122 – volume: 53 start-page: 266 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib47 article-title: Airborne grass (Poaceae) pollen in southern Spain. Results of a 10-year study (1987–1996) publication-title: Allergy doi: 10.1111/j.1398-9995.1998.tb03886.x – volume: 108 start-page: S147 issue: Suppl 5 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib1 article-title: Allergic rhinitis and its impact on asthma publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2001.118891 – year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib43 article-title: Statistical considerations in analysing health care resource utilization and cost data – ident: 10.1016/j.rmed.2007.05.003_bib19 – volume: 37 start-page: 53 issue: 1 year: 1996 ident: 10.1016/j.rmed.2007.05.003_bib45 article-title: EuroQol: the current state of play publication-title: Health Policy doi: 10.1016/0168-8510(96)00822-6 – volume: 111 start-page: 6 year: 1997 ident: 10.1016/j.rmed.2007.05.003_bib8 article-title: One airway, one disease publication-title: Chest doi: 10.1378/chest.111.2_Supplement.11S – volume: 8 start-page: 245 issue: 3 year: 1995 ident: 10.1016/j.rmed.2007.05.003_bib29 article-title: Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation publication-title: Pharmacoeconomics doi: 10.2165/00019053-199508030-00007 – ident: 10.1016/j.rmed.2007.05.003_bib30 – volume: 25 start-page: 47 year: 2005 ident: 10.1016/j.rmed.2007.05.003_bib42 article-title: Asthma: prevalence and cost of illness publication-title: Eur Respir J doi: 10.1183/09031936.04.00116203 – volume: 117 start-page: 802 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib23 article-title: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.12.1358 – volume: 61 start-page: 185 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib24 article-title: Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis publication-title: Allergy doi: 10.1111/j.1398-9995.2005.00949.x – volume: 59 start-page: 373 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib10 article-title: ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma publication-title: Allergy doi: 10.1111/j.1398-9995.2003.00468.x – volume: 95 start-page: 258 year: 2001 ident: 10.1016/j.rmed.2007.05.003_bib39 article-title: Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study publication-title: Respir Med doi: 10.1053/rmed.2001.1031 – volume: 24 start-page: 758 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib3 article-title: Prevalence and rate of diagnosis of allergic rhinitis in Europe publication-title: Eur Respir J doi: 10.1183/09031936.04.00013904 – volume: 33 start-page: 206 issue: 2 year: 2003 ident: 10.1016/j.rmed.2007.05.003_bib15 article-title: Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study publication-title: Clin Exp Allergy doi: 10.1046/j.1365-2222.2003.01587.x – volume: 61 start-page: 855 issue: 7 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib17 article-title: Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children publication-title: Allergy doi: 10.1111/j.1398-9995.2006.01068.x – volume: 117 start-page: 721 issue: 3 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib18 article-title: A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2006.01.023 – volume: 81 start-page: 401 issue: 5 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib11 article-title: Allergen specific immunotherapy: therapeutic vaccines for allergic diseases allergy, World Health Organization and American Academy of Allergy, asthma and immunology publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)63136-5 – volume: 101 start-page: 352 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib7 article-title: The impact of allergic rhinitis on bronchial asthma publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(98)70218-0 – volume: 114 start-page: 851 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib40 article-title: Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2004.07.012 – volume: 117 start-page: 34 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib4 article-title: Changes in the prevalence of asthma and allergies among children and adolescents in Italy: 1999–2002 publication-title: Pediatrics doi: 10.1542/peds.2004-2709 – volume: 12 start-page: 1322 issue: 6 year: 1998 ident: 10.1016/j.rmed.2007.05.003_bib37 article-title: Brugues J: cost of asthma according to the degree of severity publication-title: Eur Respir J doi: 10.1183/09031936.98.12061322 – volume: 111 start-page: 437 issue: 3 year: 2003 ident: 10.1016/j.rmed.2007.05.003_bib20 article-title: Noninjection routes for immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2003.129 – volume: 59 start-page: 62 issue: 1 year: 2005 ident: 10.1016/j.rmed.2007.05.003_bib35 article-title: Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and Spain publication-title: Int J Clin Practice doi: 10.1111/j.1742-1241.2005.00347.x – volume: 61 start-page: 527 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib48 article-title: The use of quality-adjusted life-years in cost-effectiveness studies publication-title: Allergy doi: 10.1111/j.1398-9995.2006.01053.x – volume: 23 start-page: 723 year: 2004 ident: 10.1016/j.rmed.2007.05.003_bib41 article-title: Asthma severity and medical resource utilisation publication-title: Eur Respir J doi: 10.1183/09031936.04.00004904 – ident: 10.1016/j.rmed.2007.05.003_bib49 – volume: 16 start-page: 191 year: 2007 ident: 10.1016/j.rmed.2007.05.003_bib25 article-title: Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study publication-title: Qual Life Res doi: 10.1007/s11136-006-9110-3 – volume: 118 start-page: 434 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib26 article-title: Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2006.05.003 – ident: 10.1016/j.rmed.2007.05.003_bib31 – volume: 50 start-page: 405 year: 1995 ident: 10.1016/j.rmed.2007.05.003_bib13 article-title: Grass pollen allergen specific immunotherapy. Efficacy and safety during a 4-year follow-up study publication-title: Allergy doi: 10.1111/j.1398-9995.1995.tb01170.x – volume: 97 start-page: 615 issue: 5 year: 2006 ident: 10.1016/j.rmed.2007.05.003_bib22 article-title: Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the SPAI study publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)61090-3 |
| SSID | ssj0009440 |
| Score | 2.077887 |
| Snippet | Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass pollen induced... Summary Background Allergic rhinoconjunctivitis is a global health problem. Around 14 million people in Spain, France, Italy, and Austria suffer from grass... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1885 |
| SubjectTerms | Adolescent Adult Aged Allergen specific immunotherapy Allergens - economics Allergens - therapeutic use Biological and medical sciences Conjunctivitis, Allergic - economics Conjunctivitis, Allergic - prevention & control Cost-Benefit Analysis Cost-effectiveness Desensitization, Immunologic - economics Desensitization, Immunologic - methods Drug Costs - statistics & numerical data Female Grass allergen tablet Grass pollen allergy Health Resources - utilization Humans Male Medical sciences Middle Aged Non tumoral diseases Otorhinolaryngology. Stomatology Pneumology Poaceae Pollen - immunology Prospective Studies Pulmonary/Respiratory QALY Quality-Adjusted Life Years Rhinitis, Allergic, Seasonal - economics Rhinitis, Allergic, Seasonal - prevention & control Rhinoconjunctivitis Tablets Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| Title | Cost-effectiveness of GRAZAX ® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0954611107001904 https://www.clinicalkey.es/playcontent/1-s2.0-S0954611107001904 https://dx.doi.org/10.1016/j.rmed.2007.05.003 https://www.ncbi.nlm.nih.gov/pubmed/17611095 https://www.proquest.com/docview/1035047243 https://www.proquest.com/docview/68134246 |
| Volume | 101 |
| WOSCitedRecordID | wos000249092300005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1532-3064 dateEnd: 20200131 omitProxy: false ssIdentifier: ssj0009440 issn: 0954-6111 databaseCode: AIEXJ dateStart: 19950901 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6FFiEkhPgnUIIP9FQ5stdr7-4xRKGAoKpKgIjLyj9raBQ5kZ1UfQyehIfgyZj9sd2mTaEHLlZkex3b83nmm9nZGYReAQfNcZKFLiFB5BK1RjfhLHFx5kuaRhn2pS7i-oEeHLDJhB92Oj_rtTAnM1oU7PSUL_6rqGEfCFstnb2GuJuLwg74DUKHLYgdtv8k-OG8WromTaPWZEAI948G3waT3SHeHYx0auHC1m4yfPF7CSRadWwAI7QHbvpKpQWUP46LOfjLU7B9usnEsU6e1V33VAM1E8k_S2-Pzkzcr8_aD-NCleHVZHW__7XfKOX5ambDQIf9183uLyoQWyR6Ij_SKvtz_1yIgjY5WG2skYCParVqrXbbM1Z1ZrlRoj4zXXysQfaZaYN8QdmbuMO0X8ID2WKUKkAWtKatns5fs3hNHmKd4jYV6hqqJScVXih0-dhtTEMOenJ78G40ed8WciZ6kW3zSHYhlskZXL-TTWTnziKu4BPMTe-Uzc6NJjnje-iu9U6cgUHVfdSRxQN066OV5EM0uwguZ547Bly_fzkALKcFljqkgeUYYDkWWM4lwIJjTg0sxwDrERq_GY2Hb13br8NNgcYu1fedkszLQ8wl8xJJaOpxFrA4xQGPaeyliZR5lnM_DrCfp16WkTjkEUuxDIBWPkZbAET5FDlewgjLPQncOSYkzjhLeQCeewiEWaVVdpFfv1eR2lr2qqXKTGyWaBftNWMWppLLlWcHtbhEvUYZrKoA7F05il42SlZWP1TCFxUWnvik8KPg46m8D-6RLgqbkZb7Gk7713_sncNS-2iMM_AOWBft1OAS7V2ofAJCMYHxL5vDYFjUbGFcyPmqEhHzA4LVu35iINlemkaqTnH47Fpv9Dm63eqGHbS1LFfyBbqZngDGyh66QSesZz-2P79s-RM |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-effectiveness+of+GRAZAX%C2%AE+for+prevention+of+grass+pollen+induced+rhinoconjunctivitis+in+Southern+Europe&rft.jtitle=Respiratory+medicine&rft.au=Canonica%2C+G.W.&rft.au=Poulsen%2C+P.B.&rft.au=Vestenb%C3%A6k%2C+U.&rft.date=2007-09-01&rft.issn=0954-6111&rft.volume=101&rft.issue=9&rft.spage=1885&rft.epage=1894&rft_id=info:doi/10.1016%2Fj.rmed.2007.05.003&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_rmed_2007_05_003 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09546111%2FS0954611107X01884%2Fcov150h.gif |